Novo Nordisk hits DKK 32,858m profit

Novo Nordisk just put up a quarter that looked strong on the surface and more complicated underneath. Profit beat expectations. Guidance went up. The obesity franchise still has real demand behind it. But the market is no longer treating “more Wegovy scripts” as the whole story — now the question is whether Novo can keep growing while pricing gets uglier. ### What happened today? Novo Nordisk said first-quarter 2026 adjusted operating profit came in at DKK 32.858 billion, ahead of expectations, and it raised its full-year 2026 outlook. The company said the upgrade was driven by stronger GLP-1 sales expectations, especially from Wegovy, plus continued growth outside the U.S. The stock rose in early trading after the release. ### Why is “adjusted” doing so much work? Because the clean-looking headline numbers are not the whole quarter. Reported Q1 sales were DKK 96.8 billion, up 32% at constant exchange rates, and reported operating profit was DKK 59.6 billion, up 65% at CER. But Novo also highlighted adjusted sales of DKK 70.1 billion and adjusted operating profit of DKK 32.9 billion after excluding a non-recurring USD 4.2 billion reversal tied to the U.S. 340B Drug Pricing Program. ### So was the business actually strong? Yes — but in a narrower, more operational sense than the raw reported numbers suggest. The quarter was helped by stronger-than-expected sales of Novo’s new obesity pill, which investors have been watching closely because it is one of the clearest ways for Novo to defend share against Eli Lilly. That better pill performance is a big reason the company felt comfortable nudging guidance higher. ### Then why are investors still uneasy? Because obesity drugs are becoming a pricing fight, not just a supply-and-demand story. Investors want proof that rising prescription volume can offset lower net prices as Novo and Lilly compete more aggressively. That is the real tension in the stock now — more patients are good, but not if every extra prescription comes with thinner economics. ### What did Novo change in its outlook? Novo said its 2026 outlook for adjusted sales growth and adjusted operating profit growth is now -4% to -12% at constant exchange rates, excluding the 340B reversal. That sounds odd next to a guidance raise, but the important point is that the company lifted its expectations relative to what it had said before, mainly because GLP-1 demand is coming in better than feared. The negative range reflects pricing pressure and policy effects, not a collapse in volume. ### Why does the 340B item matter so much? Because it can make the quarter look healthier than the underlying business really is. A provision reversal is basically an accounting giveback — real in the statements, but not the same as selling more medicine at better margins. If you are trying to judge whether Novo is winning the obesity market on fundamentals, you have to strip that out first. ### What is the market really watching now? Price-volume-mix. That sounds wonky, but it is simple: are sales rising because Novo is selling more units, because prices are holding up, or because the product mix is improving? In this phase of the obesity race, that bridge matters more than the headline profit beat. A company can post big revenue growth and still be losing net income. ### Bottom line Novo Nordisk had a good quarter, and the guidance raise was real. But the cleanest read is not “problem solved.” It is “demand is there, competition is harder, and every future quarter will be judged on whether volume can outrun price pressure.”